SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its ...
Kazia Therapeutics (KZIA) provided a regulatory update on paxalisib for the treatment of glioblastoma, GBM, following its Type C clinical meeting with the United States Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback